Principal Financial Group Inc. Purchases 2,884 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Principal Financial Group Inc. raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 126,337 shares of the company's stock after buying an additional 2,884 shares during the period. Principal Financial Group Inc. owned about 0.44% of Krystal Biotech worth $22,779,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Fifth Third Bancorp increased its stake in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Krystal Biotech in the fourth quarter worth $95,000. GAMMA Investing LLC increased its stake in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after purchasing an additional 432 shares in the last quarter. Covestor Ltd increased its stake in shares of Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after purchasing an additional 642 shares in the last quarter. Finally, US Bancorp DE increased its stake in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after purchasing an additional 82 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

KRYS stock traded down $1.59 during trading on Friday, hitting $148.15. 93,984 shares of the company's stock traded hands, compared to its average volume of 319,819. Krystal Biotech, Inc. has a 52 week low of $122.80 and a 52 week high of $219.34. The business has a fifty day simple moving average of $136.18 and a 200 day simple moving average of $156.34. The stock has a market capitalization of $4.28 billion, a price-to-earnings ratio of 35.61 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on KRYS shares. Citigroup reissued a "neutral" rating and issued a $176.00 price objective (up from $155.00) on shares of Krystal Biotech in a research note on Wednesday. HC Wainwright restated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, June 24th. Guggenheim dropped their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $213.75.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).